wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Lipids and ASCVD

Total questions: 20

Worksheet time: 30mins

Name
Class
Date
1.

What are the two sources of lipids?

a)

exogenous

b)

endogenous

c)

indigenous

d)

cytoplasmic

2.

Endogenous lipids are produced in what part of the body?

a)

kidneys

b)

heart

c)

liver

d)

gall bladder

3.

Defined as acute coronary syndromes, a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin.

a)

Atherosclerosis

b)

Cardiometabolic syndrome

c)

Atherosclerotic Cardiovascular Disease

d)

Dyslipidemia

4.

Defined as chronic, progressive disease characterized by the accumulation of fatty and fibrous material in the innermost layer of arteries that results in the formation of atherosclerotic plaques.

a)

Hyperlipidemia

b)

Myocardial infarction

c)

Atherosclerosis

d)

Heart Failure

5.

What transports lipids into the tissues?

a)

lipoproteins

b)

Apolipoproteins

c)

chylomicrons

d)

VLDL

6.

What is the most abundant atherogenic lipoprotein?

a)

Chylomicron

b)

VLDL

c)

IDL

d)

LDL

7.

Long term exposure to LDL-C is a key predictor of ASCVD risk.

a)

True

b)

False

8.

Reducing LDL-C can slow the progression of plaque volume but does not regress plaque volume.

a)

True

b)

False

9.

In individuals without established ASCVD but at high risk of an ASCVD event, low or moderate risk factor modification is a priority

a)

True

b)

False

10.

What is the indication of Sybrava?

a)

Adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia

b)

For NYHA Class II - IV adult patients

c)

Adults with controlled LDL-C

11.

What is the recommended dose of Sybrava?

a)

The recommended dose is 284 mg administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months.

b)

The recommended dose is 300 mg administered as a single intramuscular injection: initially, again at 3 months, followed by every 6 months

c)

The recommended dose is 284 mg administered as a single subcutaneous injection: initially, again at 6 months, followed by every 9 months

d)

The recommended dose is 300 mg administered as a single intradermal injection: initially, again at 6 months, followed by every 6 months.

12.

Dose adjustment is required for patients with mild to moderate hepatic impairment.

a)

True

b)

False

13.

For patients on dialysis taking Sybrava, hemodialysis should not be performed for at least how many hours?

a)

for at least 24 hrs

b)

for at least 48hours

c)

for at least 72 hours

d)

should never be performed

14.

What is the most common adverse event of Sybrava?

a)

pain at the injection site

b)

hyperuricemia

c)

hypotension

d)

dizziness

15.

Which of the following describes inclisiran?

a)

double stranded siRNA

b)

PCKS9 inhibitor

c)

HMG-CoA reductase inhibitors

d)

Galnac conjugate

16.

Following a single subcutaneous administration of 284 mg of inclisiran, LDL-C reduction was apparent within how many days post-dose?

a)

7 days

b)

10 days

c)

14 days

d)

28 days

17.

Inclisiran binds with what receptor via 3x-GAlNac?

a)

LDL receptor

b)

Apoprotein receptors

c)

asialoglycoprotein receptors

d)

argonaute

18.

As inclisiran enters the cytoplasm, it is loaded onto what type of complex?

a)

DNA induced silencing complex

b)

LDL induced silencing complex

c)

RNA induced silencing complex

d)

mRNA induced complex

19.

What cleaves the passenger strand and separates it to the guide strand as inclisiran is loaded onto the RISC?

a)

Arganine

b)

Argonaute-2

c)

PCSK9

d)

mRNA

20.

Inclisiran prevents the synthesis of PCKS9 resulting to more LDL-C receptors and increased uptake of LDL.

a)

True

b)

False